Previous cohort-based studies have reported a reduced risk of cancers such as colorectal cancer [23], pancreatic cancer [24], and hepatocellular carcinoma [25] after treatment with GLP-1 RAs. This evidence concerns the gene GCG and familial pancreatic carcinoma.